Genmab A/S
GMAB
$20.25
$0.050.25%
Weiss Ratings | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Fair | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | C | |||
Rating Factors | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Excellent | |||
Efficiency Index | Excellent | |||
Solvency Index | Excellent | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.65 | |||
Price History | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -7.85% | |||
30-Day Total Return | 5.41% | |||
60-Day Total Return | 0.55% | |||
90-Day Total Return | -10.99% | |||
Year to Date Total Return | -3.57% | |||
1-Year Total Return | -31.68% | |||
2-Year Total Return | -43.69% | |||
3-Year Total Return | -43.56% | |||
5-Year Total Return | 9.43% | |||
52-Week High % Change | -34.88% | |||
52-Week Low % Change | 8.40% | |||
Price | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $31.02 | |||
52-Week Low Price | $18.64 | |||
52-Week Low Price (Date) | Feb 10, 2025 | |||
52-Week High Price (Date) | Mar 26, 2024 | |||
Valuation | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 12.92B | |||
Enterprise Value | 9.98B | |||
Price/Earnings (TTM) | 1.15 | |||
Earnings Per Share (TTM) | 17.55 | |||
Earnings Per Share Growth | 82.42% | |||
Price/Earnings To Growth | 0.01 | |||
Price/Sales (TTM) | 0.42 | |||
Price/Book (Q) | 0.25 | |||
Enterprise Value/Revenue (TTM) | 3.20 | |||
Price | $20.25 | |||
Enterprise Value/EBITDA (TTM) | 9.43 | |||
Enterprise Value/EBIT | 9.84 | |||
Market Cap Category | Large Cap | |||
Dividends and Shares | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 64.15M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 45 70 20 27 28 | |||
Address | -- | |||
Website | www.genmab.com | |||
Country | Denmark | |||
Year Founded | 1998 | |||
Profitability | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 32.53% | |||
Profit Margin | 36.29% | |||
Management Effectiveness | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 10.94% | |||
Return on Equity | 23.15% | |||
Income Statement | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 3.12B | |||
Total Revenue (TTM) | 3.12B | |||
Revenue Per Share | $48.63 | |||
Gross Profit (TTM) | 2.98B | |||
EBITDA (TTM) | 1.06B | |||
EBIT (TTM) | 1.01B | |||
Net Income (TTM) | 1.13B | |||
Net Income Avl. to Common (TTM) | 1.13B | |||
Total Revenue Growth (Q YOY) | 33.98% | |||
Earnings Growth (Q YOY) | 441.45% | |||
EPS Diluted (TTM) | 17.55 | |||
EPS Diluted Growth (Q YOY) | 457.77% | |||
Balance Sheet | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 2.93B | |||
Cash Per Share (Q) | $45.66 | |||
Total Current Assets (Q) | 3.87B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 5.09B | |||
Current Ratio (Q) | 5.248 | |||
Book Value Per Share (Q) | $80.18 | |||
Total Assets (Q) | 6.36B | |||
Total Current Liabilities (Q) | 736.87M | |||
Total Debt (Q) | 142.85M | |||
Total Liabilities (Q) | 1.27B | |||
Total Common Equity (Q) | 5.09B | |||
Cash Flow | GMAB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -1.43B | |||
Cash from Financing (TTM) | -567.11M | |||
Net Change in Cash (TTM) | -721.68M | |||
Levered Free Cash Flow (TTM) | 847.69M | |||
Cash from Operations (TTM) | 1.13B | |||